Clinical Characteristics and Overall Survival of Large Cell Neuroendocrine Carcinoma (LCNEC) Compared to Other Subtypes of Lung Cancer: Results of a Population-based Registry Abstract #1192

Introduction: LCNEC is a rare non-small cell lung cancer subtype and clinical behavior is unclear.
Aim(s): To analyze incidence, patient (pt) characteristics, metastatic pattern and overall survival (OS) of LCNEC and compare data with small-cell (SCLC), squamous cell (SqCC) and adenocarcinomas (AdC).
Materials and methods: Histologically confirmed LCNEC, SCLC, SqCC and AdC cases diagnosed between 2003-2012 were selected from the Netherlands Cancer Registry. Cohorts of stage I-II, III and IV disease were compared for pt characteristics, metastasis at diagnosis (≥2006) and OS. Multivariate Cox regression was performed; if non-proportional, time dependent Hazard ratios (HR) were reported.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: MD Jules Derks
Keywords: LCNEC, lung

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2922 Clinicopathological Characteristics of Borderline Pulmonary Neuroendocrine Neoplasms
Introduction: According to the WHO 2015 classification pulmonary neuroendocrine neoplasms (NENs) are subdivided in carcinoids and neuroendocrine carcinoma (small cell lung carcinoma and large cell neuroendocrine carcinoma (LCNEC)), based on the presence of necrosis and mitotic index (MI). However, in some NENs a discrepancy is observed between grade of differentiation and proliferation rate.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Pathology - grading, staging
Presenting Author: MD Bregtje Hermans
#1778 Chemotherapy for Pulmonary Large Cell Neuroendocrine Carcinomas: Does the Regimen Matter?
Introduction: Metastatic pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare disease and the most effective chemotherapy regimen is debated, i.e. small cell lung carcinoma (SCLC) or non-small cell lung carcinoma (NSCLC) chemotherapy.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment – Chemotherapy, medical treatment - others
Presenting Author: Jules Derks
Keywords: lcnec, chemotherapy, nec, lung
#3052 Unique Metastatic Patterns in Neuroendocrine Neoplasms of Different Primary Origin
Introduction: Neuroendocrine neoplasms (NEN) can originate in different organs, e.g. in the gastro-enteric tract (GE), pancreas (P) or lung (L). Despite similarities in clinical and pathological characteristics in tumors of another origin, differences also exist. This might apply to metastatic patterns as well, but only limited data is available so far.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD Bregtje Hermans
#2724 Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV
Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Anna Łowczak
#3056 Multi-Omic Characterization and Evolution of Neuroendocrine Neoplasm Organoids
Introduction: Molecular characterizations of neuroendocrine neoplasm (NENs) have unveiled candidate alterations associated with aggressiveness and suggested that the molecular link between neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) might be subtler than initially thought. For example, we have recently unveiled a new entity of pulmonary carcinoids (supra-carcinoids) with carcinoid-like morphology yet the molecular and clinical features of large cell neuroendocrine carcinoma (LCNEC). Testing hypotheses to explain aggressiveness and the possibility of progression or transition from NET to NEC through the accumulation of genetic anomalies requires in vitro and in vivo experimental models.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: Dr Matthieu Foll